b1banpc.jpg b1banph.jpg

GenSci

A pioneering genetic engineering pharmaceutical company with nearly 30 years of unwavering dedication to the healthcare industry

About GenSci

Changchun GeneScience Pharmaceuticals Co., Ltd. (GenSci), established in 1997, is a subsidiary of Changchun High-Tech Industries (Group) Co., Ltd. (stock code 000661). As a pioneering genetic engineering pharmaceutical company, GenSci stands as Asia's largest manufacturing base for recombinant human growth hormone and the world's exclusive provider of a comprehensive range of recombinant human growth hormone products.


Driven by the vision of becoming a global leader in pediatric and women's health, GenSci focuses on improving the health and well-being of children and women by offering innovative solutions to address unmet medical needs. The company has expanded its product portfolio beyond its core strengths to include adult endocrinology, dermatology, rheumatology & immunology and oncology with a commitment to addressing more healthcare challenges in diverse therapeutic areas.


Today, GenSci has seamlessly integrated services, marketing, production, and R&D into a cohesive framework. Our global strategy has been marked by a strategic team layout in key regions, including the USA, Europe, and Singapore, reinforcing our commitment to offering unparalleled healthcare solutions to patients globally.

324324.jpg
  • 1997

    Establishment of Changchun GeneScience Pharmaceuticals Co., Ltd.

  • 6800+

    Employees

  • 12+

    Products Serving Countries and regions

  • 1,500+

    R&D personnel

  • 75+

    Patents

Our Values

  • b1img03.jpg
    Integrity

    We are steadfast in our commitment to ethical conduct and regulatory compliance, which forms the bedrock of our enduring legacy. Integrity is more than value; it is the essence of our corporate identity, steering every decision we make.

  • b1img05.jpg
    Innovation

    Innovation is our driving force. We are tireless in our pursuit of seeking opportunities and embracing differentiation, elevating modest ventures to benchmarks of excellence within our industry.

  • b1img04.jpg
    Excellence

    With a forward-looking perspective, we shape our present with strategic foresight. We meet every challenge with a pioneering spirit, enhancing our efficiency, and setting unassailable goals that propel us toward excellence.

  • b1img06.jpg
    Passion

    Central to our ethos is a deep-seated passion for the well-being of our patients and our team. We foster a culture that is rich in compassion and enthusiasm, ensuring that our professional excellence is matched by the genuine care we extend to every individual we engage with.

Milestones

2023

Shanghai Global Innovation Center Inaugurated

To accelerate the R&D process and bring more groundbreaking products and therapies to patients globally


2015

National Science and Technology Progress Second Class Prize

Awarded for excellence in original science and technology


2014

Jintrolong® PEG-Somatropin

The world's first long-acting growth hormone injection, taking the lead globally for a decade


2008

Genfulin® Molgramostim Gel

Pioneered as a leading product in wound healing and tissue repair


2005

Jintropin® AQ Somatropin Injection

The first liquid recombinant human growth hormone in Asia


1998

Jintropin® Somatropin for Injection

The first recombinant human growth hormone produced in China


1997

Establishment of GenSci

Featuring genetic engineering, we began our journey to enhance the health of children with growth deficiencies in China